2022 ACOG Annual Clinical & Scientific Meeting

Postpartum depression: Another outcome of the COVID-19 pandemic?

Roshini Claire Anthony, 20220608180001

Several studies presented at ACOG 2022 have raised the question as to whether postpartum depression (PPD) is one of the mental health outcomes of the COVID-19 pandemic.

Linzagolix benefits Hb levels, mood, QoL

Roshini Claire Anthony, 20220526180001

The use of the oral GnRH antagonist linzagolix in patients with heavy menstrual bleeding (HMB) due to uterine fibroids induced multiple benefits including improved haemoglobin (Hb) levels, health-related quality of life (HRQoL), and mood, analysis of the PRIMROSE 1 and 2 trials showed.

Fezolinetant reduces hot flashes in menopausal women

Elaine Soliven, 20220521000000

Treatment with fezolinetant significantly reduced the frequency and severity of vasomotor symptoms (VMS), particularly hot flashes, in women during their menopausal phase, according to the SKYLIGHT 1* trial presented at ACOG 2022.

Once-daily, low-dose elagolix reduces HMB in premenopausal women with uterine fibroids

Elaine Soliven, 20220520000000

Once-daily (QD) administration of low-dose elagolix 150 mg led to significantly reduced heavy menstrual bleeding (HMB) in premenopausal women with uterine fibroids, according to a study presented at ACOG 2022.

Relugolix combo improves uterine fibroid symptoms regardless of fibroid location

Stephen Padilla, 20220517120000

Combination therapy with relugolix (once daily relugolix 40 mg, estradiol 1 mg, norethindrone acetate 0.5 mg) leads to improvement in heavy menstrual bleeding (HMB) and in other uterine fibroid (UF)-related symptoms independent of the location of the largest fibroid, results of a recent study have shown.

Pelvic floor dysfunction in women warrants further attention

Audrey Abella, 20220517100000

There appears to be a dearth of evidence on the management of nonrelaxing pelvic floor dysfunction (PFD), a debilitating condition characterized by tension of the pelvic floor muscles that frequently leads to pelvic pain, according to data presented at ACOG 2022.

Levonorgestrel IUD staves off heavy menses in obese nulliparous women

Elvira Manzano, 20220517000000

The use of an intrauterine device (IUD) containing levonorgestrel 52 mg cuts heavy menses in obese nulliparous women in a phase III study.

ED-dispensed mifepristone plus misoprostol improves access to early pregnancy loss care

Jairia Dela Cruz, 20220516140000

Administering mifepristone and misoprostol in the emergency departments (EDs) appears to be effective, increasing the availability of early pregnancy loss medical management services to women during the COVID-19 pandemic in the US, as shown in a study presented at the 2022 American College of Obstetricians and Gynecologists (ACOG) Annual Clinical & Scientific Meeting.

COVID-19 vaccine for pregnant women: The data so far

COVID-19 vaccine hesitancy persists in pregnant women despite recommendations

Stephen Padilla, 20220516120000

Acceptance rates of COVID-19 vaccines have remained unchanged among unvaccinated pregnant women following national recommendations, with nearly one-third of patients seeing the vaccine as something harmful to their pregnancy, according to a study.

Study questions value of quantitative blood loss measurement in caesarean births

Tristan Manalac, 20220516090000

Quantitative blood loss (QBL) is only marginally better than estimated blood loss (EBL) in measuring blood loss and detecting postpartum haemorrhage during caesarean deliveries, according to a new study presented at the 2022 Annual Clinical & Scientific Meeting of the American College of Obstetricians and Gynecologists (ACOG 2022).